Epitalon (Epithalon) Reconstitution & BAC Water Guide

There is no authoritative universal instruction stating that every 10 mg Epitalon vial should receive a particular volume of BAC water. Instead, the mathematical relationship is straightforward:

10 mg ÷ liquid volume = resulting concentration in mg/mL.

These are concentration calculations only. They are not manufacturer instructions, FDA-approved dosing instructions, clinical recommendations, or BacScience administration protocols.

For a hypothetical 20 mg quantity, the same formula applies: 20 mg ÷ liquid volume.

Use the following equation:

Example: if a mathematical example contains 10 mg of Epitalon and the final liquid volume is 2 mL:

10 mg ÷ 2 mL = 5 mg/mL.

The calculation tells you the resulting concentration. It does not determine whether the chosen diluent, concentration, route, storage conditions, or administration procedure is appropriate.

Epitalon's proposed biological activity has been investigated across several experimental systems rather than through one conclusively established human mechanism.

Earlier research investigated possible relationships between Epitalon, telomerase activity and telomere length in cultured human cells. A 2025 study reported dose-dependent telomere-length changes in several human cell lines and examined hTERT/telomerase and alternative lengthening-of-telomeres pathways. :contentReference[oaicite:5]{index=5}

Other research has investigated pineal biology and melatonin-related endpoints. FDA's 2026 review noted that the mechanisms by which Epitalon might affect melatonin or circadian rhythms remain uncertain, and it highlighted an in-vitro study in which Epitalon did not directly increase melatonin release from isolated rat pineal glands. :contentReference[oaicite:6]{index=6}

Human evidence for Epitalon is limited compared with the volume of preclinical literature. FDA's 2026 review identified three studies in which Epitalon was administered to humans: two involving sublingual administration and one involving parabulbar administration in people with congenital retinitis pigmentosa. FDA also noted that the specific chemical form used in the older studies was not always clear. :contentReference[oaicite:11]{index=11}

The strongest modern example identified by FDA was a randomized, placebo-controlled study involving 75 healthy women aged 40–50 years, primarily working night shifts. A subgroup with low urinary 6-sulfatoxymelatonin received sublingual AEDG for 20 days. The study evaluated biochemical and gene-expression endpoints rather than demonstrating a clinical treatment effect for insomnia. :contentReference[oaicite:12]{index=12}

FDA concluded that available evidence was insufficient to support Epitalon effectiveness for insomnia and that the potential clinical significance of altered melatonin measurements was unclear without corresponding clinical outcomes. :contentReference[oaicite:13]{index=13}

Reconstitution mathematics starts with the total quantity of peptide and the final liquid volume.

Worked example: 10 mg quantity

• 10 mg ÷ 1 mL = 10 mg/mL
• 10 mg ÷ 2 mL = 5 mg/mL
• 10 mg ÷ 2.5 mL = 4 mg/mL
• 10 mg ÷ 3 mL = 3.33 mg/mL
• 10 mg ÷ 5 mL = 2 mg/mL

Worked example: 20 mg quantity

• 20 mg ÷ 1 mL = 20 mg/mL
• 20 mg ÷ 2 mL = 10 mg/mL
• 20 mg ÷ 2.5 mL = 8 mg/mL
• 20 mg ÷ 3 mL = 6.67 mg/mL
• 20 mg ÷ 5 mL = 4 mg/mL

No FDA-approved Epitalon drug

FDA's 2026 briefing states that there is no applicable USP or NF drug-substance monograph for Epitalon free base or Epitalon acetate, and neither is a component of an FDA-approved drug. :contentReference[oaicite:20]{index=20}

FDA reviewed Epitalon in 2026

FDA evaluated Epitalon free base and Epitalon acetate in connection with possible inclusion on the 503A Bulk Drug Substances List. The nominations were withdrawn, but FDA continued its evaluation independently. The July 2026 briefing materials state that FDA's final determination would follow completion of the advisory-committee process and agency review. :contentReference[oaicite:21]{index=21}

Effectiveness concerns

For the insomnia use evaluated by FDA, the agency concluded that available evidence was insufficient to support effectiveness. FDA noted that available human information primarily concerned melatonin or melatonin-metabolite measurements rather than clinical insomnia outcomes. :contentReference[oaicite:22]{index=22}

Safety and quality concerns

FDA identified concerns relevant to compounded Epitalon products, including potential immunogenicity related to aggregation and peptide-related impurities. FDA also stated that it had not identified sufficient safety information for the proposed route and noted the lack of acute and repeat-dose toxicity studies in its review. :contentReference[oaicite:23]{index=23}

This distinction is especially important for Epitalon research. FDA's 2026 document states that Epitalon free base and Epitalon acetate are different active pharmaceutical ingredients and should not simply be treated as identical substances. :contentReference[oaicite:24]{index=24}

FDA's briefing lists the reported molecular weight of Epitalon free base as approximately 390.35 g/mol, while Epitalon acetate was listed at approximately 450.40 g/mol. :contentReference[oaicite:25]{index=25}

For any research material, verify the actual chemical identity, salt/acetate status, quantity, purity and certificate of analysis rather than relying only on the common name “Epitalon.”